Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,671.00-1.77%ETH$2,057.29-3.16%GOLD$4,059.70+0.73%OIL$86.26+0.26%
Smart Investors Daily
SID Premium
UC

OTC · UCBJY

UCB S.A.

Healthcare · Biotechnology

$165.27

Down-$2.49 (-1.48%)

Updated Nov 11, 2026, 4:14 AM

SID Score

5.8/10

Composite research score

Smart Money

46/100

Neutral

Market cap
53.81B
P/E ratio
34.37
Dividend yield
0.48%
52-week range
— – —
Volume
1.93K
Avg. volume
29.22K

Price performance · UCBJY

UCBJY price history

1M range · 0 trading sessions · Daily adjusted prices

UCBJY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest UCBJY news

The latest Smart Investors Daily articles mentioning UCBJY.

Stock researchCompany · Overview

UCBJY research

Overview

Company profile and research snapshot.

Company profile

UCB SA UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
—
Implied upside
—
Analysts
10
UCBJY recent ratings
DateFirmRatingTarget
Sep 22, 2026TD COWENBuy—
Sep 21, 2026BERENBERGBuy—
Sep 17, 2026BAADER EUROPE / ALPHAVALUEBuy—
Sep 4, 2026JEFFERIESHold—
Sep 1, 2026DEGROOF PETERCAMBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

UCB (ENXTBR:UCB) Raises 2026 Guidance After Strong BIMZELX And CIMZIA Demand

UCB raised its full-year 2026 guidance, now targeting revenue growth in the low 20% range and adjusted EBITDA expansion in the low to mid 40% range, after stronger than expected demand for BIMZELX and CIMZIA. The new outlook suggests UCB is extracting more operating leverage from its growing immunology portfolio, as higher pharmaceutical volumes appear to scale faster than underlying cost growth. We will explore how UCB's upgraded 2026 guidance, driven by BIMZELX and CIMZIA demand, reshapes...

Yahoo · Oct 10, 2026

Is UCB (ENXTBR:UCB) Undervalued As It Expands Its Biologics Campus In Georgia?

UCB (ENXTBR:UCB) just dedicated the future site of a large biologics manufacturing campus in Gwinnett County, Georgia, marking a roughly €2b U.S. expansion that investors may view as a long-horizon capacity build. For context, UCB’s €203.5 share price comes after a 90 day share price return that declined 14.17% and a one year total shareholder return that declined 20.16%. This is in contrast to the three and five year total shareholder returns of 158.52% and 115.49%, which point to stronger...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By